Answers are grounded in this paper and cite their sources.
Targeted therapies have expanded treatment options for psoriatic arthritis (PsA), but clinical response, treatment continuation, and patient-perceived recovery may diverge in routine care. This review synthesized observational reports published between 1 January 2005 and 21 August 2026, distinguishing effectiveness, persistence, safety, outcome-associated factors, and residual burden. The available evidence comprised 64 publications, including 14 BIRRA reports. Synthesis retained outcome-specific definitions, analysis populations, and potential cohort overlap. Clinical and patient-reported improvements frequently coexisted with target nonattainment or persistent symptoms, although residual symptoms could not consistently be attributed to active inflammation. No synthesis met the review’s requirement for at least three sufficiently comparable independent cohorts. Two exploratory IL-17 inhibitor analyses estimated 12-month persistence at 74.9% (95% CI 17.8–95.3%) and the female-versus-male discontinuation hazard ratio at 1.89 (95% CI 0.10–37.32). These estimates were too imprecise for clinical prediction or treatment ranking. Safety comparisons were restricted by differences in exposure, ascertainment, and denominators. Associations involving sex, obesity, disease burden, and previous treatment were context dependent. Missing original search and screening records and incomplete risk-of-bias adjudication materially limit reproducibility and confidence. The review’s contribution is an integrated interpretation of distinct treatment outcomes rather than a therapeutic hierarchy. Molecular profiling offers complementary research directions but does not establish validated treatment-selection biomarkers within this evidence base.
No takes yet. Share an insight, caveat, or question.
Messina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: